U.S. markets closed

Certara, Inc. (CERT)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
17.00-0.06 (-0.35%)
Al cierre: 04:00PM EDT
16.20 -0.80 (-4.71%)
Fuera de horario: 05:42PM EDT

Certara, Inc.

100 Overlook Center
Suite 101
Princeton, NJ 08540
United States
609 716 7900
https://www.certara.com

Sector(es)Healthcare
IndustriaHealth Information Services
Empleados a tiempo completo1,338

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. William F. Feehery Ph.D.CEO & Director1.32MN/D1971
Mr. Leif E. PedersenPresident & Chief Commercial Officer609.11kN/D1965
Mr. John E. Gallagher IIISVP, Principal Accounting Officer & Chief Financial Officer1.07MN/D1973
Dr. Robert P. Aspbury Ph.D.President of Certara Scientific Software552.23kN/D1972
Dr. Patrick F. Smith Pharm.D.President of Certara Drug Development Solutions582.02kN/D1971
Mr. Max KanevskyChief Technology OfficerN/DN/DN/D
Prof. Amin Rostami PharmD, Ph.D., FCPChief Scientific OfficerN/DN/DN/D
Mr. Richard M. TraynorSenior VP, General Counsel & SecretaryN/DN/D1972
Mr. Ron DiSantisSenior Vice President of Corporate DevelopmentN/DN/DN/D
Ms. Sheila Rocchio MBAChief Marketing OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Gestión corporativa

La calificación ISS Governance QuickScore de Certara, Inc. a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 7; Junta: 5; Derechos del accionista: 8; Compensación: 4.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.